Oxaliplatin-induced immune-mediated cytopenias: a case report and literature review.

Oxaliplatin is a third-generation platinum antineoplastic agent that commonly causes diarrhea, nausea, vomiting, myelosuppression, and peripheral neuropathy. Less common adverse effects that are increasingly being reported include acute immune-mediated thrombocytopenia, hemolytic anemia, and pancytopenia. Here, we report a patient case of suspected oxaliplatin-induced immune-mediated thrombocytopenia and a thorough literature evaluation of acute oxaliplatin-induced immune-mediated thrombocytopenia, hemolytic anemia, and pancytopenia that has yet to be reported until now. There have been 39 previously published reports of these cytopenic events with a median number of 16 treatment cycles prior to presentation. Patients experiencing unusual signs and symptoms such as chills, rigors, fever, back pain, abdominal pain, ecchymosis, hematemesis, hematuria, dark urine, hematochezia, petechiae, epistaxis, or mental status changes during or shortly after an oxaliplatin infusion should have complete blood counts ordered and evaluated promptly.

Anemia and hypocholesterolemia.

The authors reviewed the available data on the relationship between hypocholesterolemia and anemia with various etiologies. The data were collected from sources identified by a MEDLINE search of English-language literature published between 1966 and 2001 and bibliographies of relevant articles. The study selection included primary research articles, metaanalyses, and abstracts concerning the relation between hypocholesterolemia and anemia. Textbooks, meeting proceedings, and reference lists were also searched. Despite differences in study design, a relation was found between hematocrit and serum cholesterol levels and between hemoglobin and cholesterol levels. Further studies are required to determine the exact etiology and clinical significance of these findings.